CalciMedica Inc. (NASDAQ:CALC) Short Interest Down 47.6% in July

CalciMedica Inc. (NASDAQ:CALC) was the recipient of a large decrease in short interest in the month of July. As of July 31st, there was short interest totaling 503,070 shares, a decrease of 47.6% from the July 15th total of 960,731 shares. Based on an average daily volume of 277,430 shares, the short-interest ratio is currently 1.8 days. Approximately 4.4% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

CALC has been the topic of a number of research analyst reports. HC Wainwright reissued a “neutral” rating on shares of CalciMedica in a report on Wednesday, July 29th. Weiss Ratings cut shares of CalciMedica from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday. Finally, UBS Group reissued a “neutral” rating on shares of CalciMedica in a report on Thursday. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $10.00.

CalciMedica Trading Down 1.9%

CALC stock traded down $0.01 during mid-day trading on Monday, reaching $0.66. 75,988 shares of the stock traded hands, compared to its average volume of 1,053,568. The company has a debt-to-equity ratio of 1.67, a quick ratio of 5.58 and a current ratio of 5.58. CalciMedica has a one year low of $0.46 and a one year high of $7.20. The stock has a market capitalization of $10.47 million, a PE ratio of -0.49 and a beta of 0.91. The business has a 50-day moving average price of $0.81 and a two-hundred day moving average price of $0.75.

CalciMedica (NASDAQ:CALC) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.17). Equities research analysts expect that CalciMedica will post -1.05 EPS for the current year.

Insider Buying and Selling at CalciMedica

In related news, Director Fred A. Middleton bought 248,972 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were bought at an average cost of $0.80 per share, for a total transaction of $199,177.60. Following the completion of the transaction, the director owned 1,063,272 shares of the company’s stock, valued at approximately $850,617.60. This trade represents a 30.57% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 28.25% of the stock is owned by company insiders.

Institutional Investors Weigh In On CalciMedica

Large investors have recently modified their holdings of the business. Cetera Investment Advisers raised its holdings in CalciMedica by 33.1% in the second quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock worth $58,000 after purchasing an additional 9,045 shares in the last quarter. 180 Wealth Advisors LLC grew its position in shares of CalciMedica by 297.2% in the 1st quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock worth $68,000 after buying an additional 94,650 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of CalciMedica by 45.0% during the 1st quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock worth $69,000 after acquiring an additional 39,775 shares in the last quarter. Jane Street Group LLC bought a new position in shares of CalciMedica during the 4th quarter worth approximately $127,000. Finally, Envestnet Asset Management Inc. lifted its position in CalciMedica by 58.2% during the second quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after acquiring an additional 34,386 shares during the last quarter.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.